Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,824.66
(
0.62%
)
US TECH 100
24,364.00
(
0.50%
)
Dow Jones
48,185.80
(
0.58%
)
Brent Oil
94.45
(
-0.41%
)
Bitcoin
71,800.47
(
0.94%
)
News Focus
News Focus
Post# of 517033
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Lima4918

Send PM Follow Ignore
Followers 14
Posts 1165
Boards Moderated 0
Alias Born 06/14/2018

Lima4918

Re: kevli33 post# 217781

Tuesday, 11/05/2019 8:33:12 PM

Tuesday, November 05, 2019 8:33:12 PM

Post# of 517033
Hampel describes his work at Eisai, which is to Create “novel therapies” for “early stage of disease.”

He is NOT connecting himself to the failed, corrupt Aducanumab trial and that amyloid hypothesis.

He is going to “innovate.”

His word, “innovate”
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News